Objective measures of grape quality: From Cabernet Sauvignon grape composition to wine sensory characteristics
Publication date: Available online 27 January 2020Source: LWTAuthor(s): Jun Niimi, Oliver Tomic, Tormod Næs, Susan E.P. Bastian, David W. Jeffery, Emily L. Nicholson, Suzanne M. Maffei, Paul K. BossAbstractIn an investigation of objective measures that link grape composition to wine quality, this study sought to identify Cabernet Sauvignon grape parameters that predict the sensory properties of the corresponding wines. Eleven chemical measures comprising volatile and non-volatile compounds, enzyme activity plus standard industry harvest measurements were applied to grape samples obtained from different regions throughout South Eastern Australia over three vintages. Grapes underwent controlled vinification and the resulting wines evaluated with sensory descriptive analysis. The entire multi-vintage data sets were combined and modelled using a combination of partial least squares (PLS) and sequential and orthogonalised (SO) -PLS regression techniques. Optimal models were obtained with single sensory attributes rather than global modelling with the entire sensory profile. Five grape chemical measures, which in the main were harvest parameters, were used along and orthogonalised to model 14 sensory attributes of the Cabernet Sauvignon wines. The seven remaining measures were not used due to their poor ability to model wine sensory attributes, with enzyme activity and tannin by HPLC explaining the least. The study revealed new insights into the relationship between grape che...
AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Date: Tuesday, 03 03, 2020; Speaker: TBD, TBD; Dr. Jeremy Veenstra-VanderWeele, Columbia University; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Date: Tuesday, 03 10, 2020; Speaker: TBD, TBD; Dr. Jeff Elias, University of Virginia School of Medicine; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Date: Tuesday, 03 10, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); NIH Library Training Room
Date: Wednesday, 03 11, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Date: Thursday, 03 12, 2020; Speaker: BTRIS instructor; Building: Building 10 (Clinical Center); NIH Library Training Room